2018
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study
Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research And Treatment 2018, 171: 325-334. PMID: 29789969, PMCID: PMC6076849, DOI: 10.1007/s10549-018-4828-5.Peer-Reviewed Original ResearchConceptsHormone receptor-positive advanced breast cancerAdvanced breast cancerIncidence of gradeAdverse eventsBreast cancerPhysical functionProgression-free survival benefitMultivariable logistic regression modelAddition of bevacizumabPhase III trialsPhysical function measuresAdverse event dataFunctional Assessment MeasureIncidence of toxicityFlight of stairsLogistic regression modelsHemorrhagic eventsIII trialsSurvival benefitMedian ageThrombosis eventsRisk factorsUnivariate analysisAssessment measuresBevacizumab
2014
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal Of Cancer 2014, 111: 1532-1541. PMID: 25101563, PMCID: PMC4200088, DOI: 10.1038/bjc.2014.444.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerChemotherapy responseClinical trialsProliferation signatureBreast cancerMultivariable logistic regression modelFuture clinical trialsBasal-like diseaseBasal-like subtypeIntrinsic molecular subtypesClinical pathological dataLogistic regression modelsBLBC subtypeIntrinsic subtypesSignificant interaction testMolecular subtypesCox modelIndependent cohortTNBC heterogeneityClinical implicationsSignificant associationBLBCChemotherapyPhenotypic subtypesLow expression
2009
Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making
Gold J, Najita J, Lester S, Richardson A, Morganstern D, Chen W, Partridge A, Krop I, Winer E, Burstein H. Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. Journal Of Clinical Oncology 2009, 27: 572-572. DOI: 10.1200/jco.2009.27.15_suppl.572.Peer-Reviewed Original ResearchEarly-stage breast cancerOncotype DX recurrence scoreRecurrence scoreDX recurrence scoreAdjuvant chemotherapyClinical factorsTumor gradeChemotherapy decisionsBreast cancerMultivariable logistic regression modelStandard clinicopathologic dataProgesterone receptor expressionReceipt of chemotherapyAdjuvant chemotherapy decisionsLow recurrence scoreHigh recurrence scoreStage breast cancerSingle academic institutionLikelihood of benefitStandard clinical factorsElectronic medical recordsLogistic regression modelsChemotherapy recommendationsMenopausal statusChemotherapy administration
2006
Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density
Abusief M, Missmer S, Ginsburg E, Weeks J, Winer E, Partridge A. Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density. Journal Of Clinical Oncology 2006, 24: 10506-10506. DOI: 10.1200/jco.2006.24.18_suppl.10506.Peer-Reviewed Original ResearchRisk of amenorrheaEarly breast cancerBreast cancerDDS therapyPremenopausal womenDana-Farber Cancer InstituteMultivariable logistic regression modelChemotherapy-related amenorrheaLikelihood of amenorrheaAddition of paclitaxelDose densityEffect of paclitaxelLogistic regression modelsAdjuvant chemotherapyTamoxifen useWomen's HospitalMultivariable modelMenstrual functioningAmenorrheaAverage ageCancer InstituteMenstrual dataPatientsAlcohol useTherapy